MicroenvironmentAntigensProgressionSuppressorAntibodiesEfficacyInduceCytotoxicInfiltrationImmunosuppressionTargeting tumor cellsTherapeuticInhibition of tumorCelldex TherapeuticsNecrosis factorDomain TherapeuticsImmunotherapiesCellsAntibodyRole in immunityMetastasisImmunologyVaccinesInitiationClinicalImmune checkpointPromote tumorTissueMelanomaMutationsColorectalEffector functionCancer immunotherapyResponsesChemotherapyBiologySuppressionBehaviorPrognosisBlockadeResistanceCellPatients
Microenvironment22
- Our preliminary and published studies uncovered a remarkably better response to standard care in female glioblastoma patients than in male patients as well as sex-specific differences in signaling networks and interactions in the tumor microenvironment. (abta.org)
- A2AR & A2BR: The Adenosine A2A receptor is regarded as an important checkpoint in cancer therapy because adenosine in the immune microenvironment, leading to the activation of the A2a receptor, is negative immune feedback loop and the tumor microenvironment has relatively high concentrations of adenosine. (wikipedia.org)
- Although there is ample evidence that the chemotherapeutic drugs trigger an immune response, the efficient tumor rejection or regression is not guaranteed probably due to the massive immunosuppression within the tumor microenvironment. (thno.org)
- This work represents a novel approach for cancer immunotherapy by integrating nanotechnology and platinum-based therapeutics which not only efficiently exerts the chemotherapeutic cytotoxic effect on tumor cell but also restores immune response of immunological cells within the tumor microenvironment. (thno.org)
- First, the stimulatory or death signals are released from apoptotic tumor cells into the tumor microenvironment. (thno.org)
- During the early phase of tumor development, immune cells could spontaneously infiltrate into the tumor microenvironment to evoke an immune response and fight against the growth of the tumor. (thno.org)
- In addition, a deeper understanding of the complex interplay of cells in the tumor microenvironment will lead to therapies directed at the specific mechanism of immune suppression in a specific patient. (genengnews.com)
- Emerging evidence indicates that lncRNAs participate in crosstalk between tumor and stroma, and reprogramming of tumor immune microenvironment (TIME). (biomedcentral.com)
- Together, they form the microenvironment in which the tumor is located, namely tumor microenvironment (TME). (biomedcentral.com)
- Among the components of TME, distinct populations of innate and adaptive immune cells consist of tumor immune microenvironment (TIME). (biomedcentral.com)
- We laid particular focus on those researches that reveal how exosomes regulate the tumor immune microenvironment (TIME) and how exosomal cargos affect the progression of HCC. (hindawi.com)
- This is associated with the formation of the HCC immunosuppressive microenvironment which seriously hinders the antitumor effect of immune checkpoint inhibitors, attenuating the efficacy of immunotherapy [ 2 ]. (hindawi.com)
- HCC-derived exosomes participate in changing tumor progression by regulating the tumor microenvironment and tumor immune status [ 14 , 15 ]. (hindawi.com)
- Mechanistic investigation defined that Axl inhibition reprograms the immunological microenvironment leading to the increased proliferation, activation and effector function of tumor-infiltrating CD4 + and CD8 + T cells possibly through preferential accumulation and activation of CD103 + cross-presenting dendritic cells. (oncotarget.com)
- 1,2 KIR3DL3, expressed on T and NK cells in the tumor microenvironment, suppresses immune responses following engagement with HHLA2. (bmj.com)
- The tumor microenvironment (TME) plays a crucial role in tumor progression. (bvsalud.org)
- However, the molecular mechanisms underlying the complex communication network of the tumor microenvironment merited further evaluation. (bvsalud.org)
- by contributing to sustained chronic inflammation as a result of modulating the immune cells so that the tumor microenvironment is activated by invasion of immune suppressive regulatory T cells, and/or by mediating the release of inflammatory mediators by immune cells with no anti-tumor activity. (jscimedcentral.com)
- The interplay between the gliomas, the tumor microenvironment and infiltrating immune cells can hold key information to how to utilize PD-L1/PD-1 directed immunotherapies to successfully treat GBM patients. (jscimedcentral.com)
- This divergent effect might be dependent on the glioma subclass, expression levels of PD-L1 and PD-L1 regulatory molecules, but most importantly on the cell type that express PD-L1 in the tumor microenvironment. (jscimedcentral.com)
- Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. (jscimedcentral.com)
- In particular, Guadecitabine greatly enhanced the efficacy of combined ICBs by increasing effector memory CD8+ T cells, inducing effector NK cells in the spleen and reducing tumor infiltrating regulatory T cells and myeloid derived suppressor cells (MDSC), in the tumor microenvironment (TME). (biomedcentral.com)
Antigens4
- For example, antibodies specific to tumor antigens, adoptively transferred immune cells, therapeutic vaccines, and recombinant cytokines effectively boost the host immune system to recognize tumor cells as pathogens and eliminate them [ 1 - 3 ]. (thno.org)
- Then these signals are engulfed as antigens and presented by antigen-presenting cells within the tumor-derived lymph nodes. (thno.org)
- One is the ability to administer large numbers of highly selected cells with high avidity for tumor antigens that can recognize shared and patient-specific mutated (neo) antigens. (biomedcentral.com)
- Pre-requisite of tumor response to ICBs is the co-expression by cancer cells of immunogenic tumor antigens and targetable immune checkpoint molecules. (biomedcentral.com)
Progression11
- Further compounding this conundrum is the difficulty in accurately assessing response, as an increase in contrast enhancement on standard post-contrast MRI can be seen in treatment-related changes and true tumor progression. (abta.org)
- Whether C. tropicalis participates in the progression of CRC and immunotherapy resistance through regulating the tumor cell-intrinsic PD-1 remains to be further elucidated. (jcancer.org)
- This shows that C. tropicalis promotes CRC progression via controlling the expression of tumor cell-intrinsic PD-1. (jcancer.org)
- C. tropicalis can down-regulate tumor cell-intrinsic PD-1 expression via enhancing tumor cells autophagy levels to promote CRC progression. (jcancer.org)
- In this paper, we reviewed the recent researches on the multiple roles of tumor-associated exosomes in the progression of HCC. (hindawi.com)
- A number of studies have proved that exosomes are important mediators for the initiation, progression, angiogenesis, and metastasis of tumors [ 10 ]. (hindawi.com)
- Accumulation of driver and passenger mutations during tumor progression. (nature.com)
- However, co-expression of HHLA2 and PD-L1 in tumors from patients with RCC is associated with worse progression free survival that those with tumors exclusively expressing PD-L1. (bmj.com)
- The triangle composed of nutrition, inflammation and immunity, and cancer illustrates how qualitative and quantitative imbalances in food intake predispose organisms, in a manner dependent on or independent of the immune system, to a time-dependent deterioration in function that culminates in the development and progression of cancer. (nature.com)
- Despite recent advances, treatment for head and neck squamous cell carcinoma (HNSCC) has limited efficacy in preventing tumor progression. (bvsalud.org)
- Thus, it can change the formation and progression of tumors by acting on human immunity. (hindawi.com)
Suppressor3
- This study shows that PD-1 is a tumor suppressor in CRC. (jcancer.org)
- Constitutional PV's in the tumor suppressor gene adenomatous polyposis coli (APC) result in constitutive activation of the Wnt signaling pathway through deregulation of β-catenin, causing downstream effects on proliferation and differentiation within colonic crypts. (aacrjournals.org)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. (jscimedcentral.com)
Antibodies7
- Anti-OX40 monoclonal antibodies have been shown to have clinical utility in advanced cancer. (wikipedia.org)
- Antibodies to GITR have been shown to promote an anti-tumor response through loss of Treg lineage stability. (wikipedia.org)
- The biotech company TG Therapeutics is working on anti-GITR antibodies ICOS: This molecule, short for Inducible T-cell costimulator, and also called CD278, is expressed on activated T cells. (wikipedia.org)
- However, potential limitations of narrowly focusing on the spike (S) protein are becoming apparent with emerging variants capable of partially escaping neutralization by vaccine induced antibodies. (geovax.com)
- Based on crystallographic studies of gp120 molecules from HIV-1 and SIV and on studies of antibody structures, a number of strategies are being pursued to induce broadly neutralizing anti-gp120 antibodies. (scielo.br)
- Thus, scientists invented two anti-PD-1 molecules (immunomodulatory antibodies) that mask PD-1 on the surface of T cells. (the-gist.org)
- Immunotherapy with anti-GD2 monoclonal antibodies (mAbs) is now considered the only important therapeutic advance in the treatment of HR neuroblastoma in the last decade. (hospitalpharmacyeurope.com)
Efficacy7
- A series of in vitro and in vivo analyses, including physical and chemical characterizations, targeting property, biosafety, and antitumor efficacy of Wpep-DGL/Pt were systematically carried out. (thno.org)
- Wpep-DGL/Pt showed potent antitumor efficacy in MDA-MB-231 cells tumor-bearing nude mice with a deficient immune system, demonstrating targeted delivery of chemotherapeutics and the resultant cytotoxicity. (thno.org)
- Furthermore, in immunocompetent mice bearing 4T1 cells tumors, Wpep-DGL/Pt activated immune cells and induced cell death proving their dual function of chemotherapeutic and immunomodulatory efficacy. (thno.org)
- Here, we found that Axl inhibition by tyrosine kinase inhibitors induces antitumor efficacy critically depending on immune effector mechanisms in two highly clinical relevant murine tumor models. (oncotarget.com)
- More importantly, we show that Axl inhibition induces an adaptive immune resistance evidenced by unregulated PD-L1 expression on tumor cells and combined Axl inhibition with PD-1 blockade mounts a potent synergistic antitumor efficacy leading to tumor eradication. (oncotarget.com)
- Chemoprevention in LS with aspirin and nonsteroidal anti-inflammatory drugs has also translated into clinical cancer, however the efficacy of such agents in FAP remains elusive when cancer is applied as an endpoint in trials rather than the use of 'indirect' endpoints such as polyp burden, and requires further elucidation of biological mechanisms in FAP. (aacrjournals.org)
- HemoHIM may be a beneficial supplement during cisplatin chemotherapy for enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin. (biomedcentral.com)
Induce3
- It is mainly expressed on mature cytotoxic T lymphocytes [ 7 , 8 ], and it can inhibit T cell function by binding with PD-L1 or PD-L2 ligand, which is mainly expressed on the surface of tumor cells, to induce immune tolerance and limit autoimmunity [ 9 ]. (jcancer.org)
- Tumor-specific neoantigens, which are expressed on tumor cells, can induce an effective antitumor cytotoxic T-cell response and mediate tumor regression. (wjgnet.com)
- vaccines The immune system is complex, yet so simple in its ability to induce nonspecific (innate) immunity and specific immune responses against pathogens, including, bacteria, viruses and parasites. (studylib.net)
Cytotoxic2
- Cisplatin (cis-diaminedichloroplatinum (II) or CDDP), a platinum-containing anticancer drug, is one of the most commonly used cytotoxic agents for the treatment of a variety of solid malignant tumors. (biomedcentral.com)
- 1. by inhibiting cytotoxic T-lymphocytes from destroying the tumor cells, 2. (jscimedcentral.com)
Infiltration2
- NK cell infiltration into tumor tissue is associated with better disease prognosis in colorectal cancer, clear cell renal cell carcinoma, and lung carcinomas ( 9 - 11 ). (frontiersin.org)
- Our results clarified the significant role of DOK5 in the prognosis of GC and offer a potential mechanism by which DOK5 expression might monitor tumor immunity-regulation of the infiltration of immune cells in GC. (hindawi.com)
Immunosuppression2
- With the expansion of immune checkpoint inhibitor treatments and the understanding of how tumors highjack and escape the immune system, even under immunostimulating treatments, GPCRs have recently emerged as strategic targets responsible of immunosuppression and treatment-resistance mechanisms. (cbinsights.com)
- Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. (jscimedcentral.com)
Targeting tumor cells1
- instead of targeting tumor cells, the goal of immunotherapy is to augment and expand the immune system's intrinsic antitumor response. (frontiersin.org)
Therapeutic5
- Therapeutic intervention aims to reverse tumor-induced NK cell suppression and sustain NK cells' tumorlytic capacities. (frontiersin.org)
- Here, we review tumor-NK cell interactions, discuss the mechanisms by which NK cells generate an antitumor immune response, and discuss NK cell-based therapeutic strategies targeting activating, inhibitory, and co-stimulatory receptors. (frontiersin.org)
- Geneva, Switzerland - 5 September 2017 â€" AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the first tranche of its Series B financing round, raising €8 million (CHF 8.8 million). (3bfuturehealth.com)
- It will also further develop its proprietary therapeutic tumour vaccination technology platform called KISIMA. (3bfuturehealth.com)
- However, in many cases, chemotherapy or radiotherapy alone cannot achieve a satisfactory therapeutic outcome, namely the complete remission of tumors, and induces severe side effects at therapeutically effective doses. (biomedcentral.com)
Inhibition of tumor1
- Finally, the innate immunity or adaptive immunity is stimulated leading to regulation and inhibition of tumor growth. (thno.org)
Celldex Therapeutics1
- The American biotech company Celldex Therapeutics is working on CDX-1127, an agonistic anti-CD27 monoclonal antibody which in animal models has been shown to be effective in the context of T cell receptor stimulation. (wikipedia.org)
Necrosis factor3
- The CD56 bright population produces immunoregulatory cytokines, including interferon-γ (IFN-γ), tumor necrosis factor-beta (TNF-B), tumor necrosis factor-α (TNF-α), granulocyte macrophage-colony stimulating factor (GMCSF), IL-10, and IL-13 ( 4 ). (frontiersin.org)
- Four stimulatory checkpoint molecules are members of the tumor necrosis factor (TNF) receptor superfamily-CD27, CD40, OX40, GITR and CD137. (wikipedia.org)
- Tuberculosis has been reported in patients treated for arthritis, inflammatory bowel disease, and other conditions with tumor necrosis factor (TNF)-alpha blockers/antagonists. (medscape.com)
Domain Therapeutics10
- Domain Therapeutics is a biopharmaceutical company with a high-level focus on immuno-oncology, specifically in the domain of G Protein-Coupled Receptors (GPCRs). (cbinsights.com)
- Domain Therapeutics was formerly known as Faust Pharmaceuticals. (cbinsights.com)
- Domain Therapeutics has filed 9 patents. (cbinsights.com)
- Domain Therapeutics will use the proceeds of this financing to i) conduct the clinical development of its EP4R antagonist, DT-9081, ii) advance two additional GPCR programs, including an anti-CCR8 antibody, to the Investigational New Drug application stage, and iii) progress its discovery-stage pipeline of a number of first-in-class assets targeting GPCRs, identified through its proprietary platforms. (cbinsights.com)
- We are pleased to welcome our new shareholders and I thank them all for their commitment at this decisive stage of our company's growth," comments Pascal Neuville, CEO of Domain Therapeutics. (cbinsights.com)
- Domain Therapeutics is leveraging its insights into GPCR science and technology to develop a robust immuno-oncology pipeline designed to harness the power of immunity and to broaden the impact of immunotherapies. (cbinsights.com)
- In addition, Domain Therapeutics scientists are hunting for biomarkers, tissue microarray data, genetic mutations and protein expression to select patients who will benefit most from its immunotherapy treatments. (cbinsights.com)
- We are very proud to co-lead this strategic financial round to support Domain Therapeutics capabilities to innovate and transform the company into a clinical-stage biotech. (biospace.com)
- Domain Therapeutics has a unique positioning in GPCR-mediated immunoresistance. (biospace.com)
- We are delighted to support Domain Therapeutics high-performing management team in transforming a comprehensive portfolio of programs into cancer treatments. (biospace.com)
Immunotherapies1
- Among tumor immunotherapies, neoantigen vaccines are in early human clinical trials and have demonstrated substantial efficiency. (wjgnet.com)
Cells42
- There is compelling clinical and experimental evidence to suggest that natural killer (NK) cells play a critical role in the recognition and eradication of tumors. (frontiersin.org)
- Efforts at using NK cells as antitumor agents began over two decades ago, but recent advances in elucidating NK cell biology have accelerated the development of NK cell-targeting therapeutics. (frontiersin.org)
- However, as tumors progress, cancerous cells develop immunosuppressive mechanisms that circumvent NK cell-mediated killing, allowing for tumor escape and proliferation. (frontiersin.org)
- However, a class of important immune-modulators is conspicuously absent: agents that utilize the power of innate immune cells to eradicate tumors. (frontiersin.org)
- An important class of innate immune cells that play a critical role in mediating the antitumor immune response is the natural killer (NK) cell. (frontiersin.org)
- First described in 1975, NK cells were initially identified as a distinct sub-population of lymphocytes by their capacity to spontaneously lyse tumor cells ( 1 ). (frontiersin.org)
- NK cells are now accepted to play an important role in both the adaptive and innate immune responses that govern infection, autoimmunity, and tumor immunosurveillance ( 2 , 3 ). (frontiersin.org)
- Acquisition of these mutations by normal cells can lead to microscopic abnormalities starting years before detectable tumors appear. (abta.org)
- Brain tumors in general are derived mostly from glial cells, astrocytes and oligodendrocytes, but not neurons. (abta.org)
- “AMAL Therapeutics is a highly innovative company with great leadership, and its novel KISIMA cancer vaccine technology platform that targets and kills tumorous cells has the potential to bring significant benefit to people with cancer. (3bfuturehealth.com)
- TIME possesses distinct populations of myeloid cells and lymphocytes to influence the immune escape of cancer, the response to immunotherapy, and the survival of patients. (biomedcentral.com)
- In addition to tumor cells, there are also important stromal components in tumor niche. (biomedcentral.com)
- The programmed cell death 1 (PD-1) receptor is an immune checkpoint molecule that induces immune tolerance and mediates the immune escape of tumor cells. (jcancer.org)
- Moreover, blocking antibody against PD-1 promotes tumor growth both in SW480 cells and mice CRC xenografts in an adaptive immune-independent manner. (jcancer.org)
- We also demonstrated that high concentrations of C. tropicalis can down-regulate tumor cell-intrinsic PD-1 expression in colon cancer cells. (jcancer.org)
- Immune checkpoint (IC) proteins are some of the most important factors that tumor cells hijack to escape immune surveillance, and inhibiting ICs to enhance or relieve antitumor immunity has been proven efficient in tumor treatment. (portlandpress.com)
- Compared with normal cells, tumor cells secrete more exosomes, and the number of exosomes secreted by different tumor cells varies dramatically [ 6 ]. (hindawi.com)
- Exosomes were first described in 1981 as ATPase-containing vesicles exfoliated from cells and were found in various normal cells and tumor cells [ 16 ]. (hindawi.com)
- NPX267 treatment augmented the ability of human NK cell lines and primary NK cells to kill HHLA2 + tumor cells in vitro. (bmj.com)
- hence, they can be applied to redirect effector cells to tumor cells. (ens-lyon.fr)
- By simultaneous recognition of two different targets, bsAbs can serve as mediators to redirections of immune effector cells, such as Natural Killers cells and T-cells, to tumor cells, in order to enhance their destruction. (ens-lyon.fr)
- These cells can be activated ex vivo to exhibit a potent antitumor effector function. (biomedcentral.com)
- Successful TIL therapy starts with the identification, enrichment, stimulation, and expansion of potent tumor-reactive T cells. (biomedcentral.com)
- NK cells coordinate tumor immunosurveillance and the immune response against pathogens. (scielo.br)
- Thus, the local immunological milieu in tissue compartments forms the nature and magnitude of the host responses, i.e., frequencies of regulatory T cells (Tregs) vs. T-helper 17 (Th17) cells, amount of pro-inflammatory cytokines vs. anti-inflammatory cytokines, extent of neutrophilia and antigen-presenting-cell (APC) activation, among others. (frontiersin.org)
- We also assessed its status regarding distinct tumor-infiltrating immune cells, using the Oncomine database, TIMER databases, GEPIA, Kaplan-Meier plotter, and UALCAN database. (hindawi.com)
- The Tumor Immune Estimation Resource (TIMER) platform has been used to assess the tumor-infiltrating immune cells of 32 cancer types in a comprehensive way. (hindawi.com)
- TIMER assesses a mass of tumor-infiltrating immune cells using the statistical analysis of the gene expression profiles [ 7 ]. (hindawi.com)
- Given the heterogeneity and complex etiology of the GBM and the origin of the tumor cells, it is not surprising that the environment that surrounds the tumors display wide varieties of responses. (jscimedcentral.com)
- In some cancers, PD-L1 expression by tumor cells correlates with a good prognosis for the patient, whereas in glioblastoma many reports suggest that it is a bad prognostic marker. (jscimedcentral.com)
- Issazadeh-Navikas S. Alerting the immune system via stromal cells is central to the prevention of tumor growth. (jscimedcentral.com)
- But sometimes our body is attacked by foreign bacteria or viruses, or worse - our own cells turn rogue and replicate out of control, creating a tumour. (the-gist.org)
- Scientists have discovered that during the initial phase when the tumour is recognised and destroyed by the immune system, some cancer cells randomly become resistant to immune reaction. (the-gist.org)
- The former are molecules that help the immune system to be more aggressive against the tumour or prevent the immune cells being fooled by the tumour. (the-gist.org)
- T cells are a type of white blood cells that play a central role in immunity. (the-gist.org)
- Several approaches to overcome resistance to ICBs are being investigated among which the addition of epigenetic drugs that are expected to act on both immune and tumor cells. (biomedcentral.com)
- Tumour cells are small in size and have no discernible cytoplasm. (hospitalpharmacyeurope.com)
- Mature Schwann cells represent the dominant component of the tumour, characteristically forming multiple fascicles covered with perineurial cells. (hospitalpharmacyeurope.com)
- In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. (studylib.net)
- Consequently, it was shown by others that tumor cells also expressed MHC-I and presented short tumor-associated peptides to immune cells [6]. (studylib.net)
- However, tumor cells can evade host's immune surveillance using a number of protective mechanisms, including downregulation of MHC-I molecules, secretion of anti-inflammatory cytokines, in other words, TGF-β and IL-10, secretion of immunosuppressive factors, VEGF, upregulation of PD-L1 and downregulation of co-stimulatory molecules thereby preventing activation of T cells, resulting in cancer invasion. (studylib.net)
- The binding of T cells expressing PD-1 and tumor cells expressing PD-L1 initiates an array of inhibitory signals resulting in reduced function and/or apoptosis of T cells [8,11] providing a mechanism for tumor cell evasion of host's immune surveillance [12-14]. (studylib.net)
Antibody2
- A now-defunct Seattle-based biotechnology company called VLST in-licensed an anti-CD40 agonist monoclonal antibody from Pfizer in 2012. (wikipedia.org)
- NPX267, a first-in-class KIR3DL3 blocking antibody, potentiates anti-tumor immunity against HHLA2 + tumors and may represent a promising approach to treat certain cancers. (bmj.com)
Role in immunity1
- In a very interesting chapter, Z. PANCER and M. D. COOPER first consider the emergence of lymphocytes as a novel circulatory cell type in vertebrates and then discuss phylogenetic aspects of the superfamily of LRR - containing proteins and their role in immunity. (scielo.br)
Metastasis1
- An in vivo study confirmed the functional role of IL-33/CXCR4 in tumor initiation and metastasis. (bvsalud.org)
Immunology3
- Recent advances in understanding of fundamental immunology have created new insights into the dynamic interactions between tumors and the immune system. (nshealth.ca)
- With a better understanding of molecular details in tumor immunology and tumor biology, tailored cancer immunotherapy is considered as a promising strategy for cancer treatment. (thno.org)
- The article also describes how cancer immunology is an emerging field that has resulted in new methods of treating cancer that boost the immune systems' responses against tumors. (stellarbiotics.com)
Vaccines3
- “AMAL Therapeutics next generation vaccines have the potential to convert and combat tumours that have so far not been accessible to the immune system. (3bfuturehealth.com)
- Unique compared to other vaccines approved or under development, the GeoVax vaccine candidate is therefore specifically designed to provide a broader and more durable level of protective immunity against SARS-CoV-2, which may protect against emerging variants while avoiding the potential side effects that can limit vaccine utility and acceptance. (geovax.com)
- Building on the response to recent outbreaks of Ebola virus disease, SARS-CoV and MERS-CoV, the R&D Blueprint has facilitated a coordinated and accelerated response to research into diagnostics, vaccines and therapeutics for the novel disease. (who.int)
Initiation1
- This research will be the first of its kind, improving our understanding of brain tumor initiation but also in providing the basis for developing sensitive methods for detecting incipient tumors where no manifestation is evident. (abta.org)
Clinical6
- The antitumor effect provided by natural killing has been observed in tumors of hematopoietic and non-hematopoietic origins and reported in diverse in vivo models and clinical series ( 8 ). (frontiersin.org)
- AMAL’s KISIMA technology demonstrated potent and multi-antigenic long lasting anti-tumour immunity and prevented tumour immune escape in pre-clinical models. (3bfuturehealth.com)
- Although ICB agents have shown outstanding clinical success, and their application has continued to expand to additional tumor types in the past decade, immune-related adverse events (irAEs) have been observed in a wide range of patients who receive ICB treatment. (portlandpress.com)
- Clinical studies have shown that many patients do not adequately respond to monospecific therapy, and often resistance to the treatment or tumor reemission has been observed. (ens-lyon.fr)
- In clinical practice, a key challenge for generating TIL products is the accessibility, quantity, and quality of tumor tissue in the era of neo-adjuvant therapy. (biomedcentral.com)
- the median age at diagnosis is 17 months.5 The clinical presentation is highly variable, ranging from a mass that causes no symptoms to a primary tumour that causes critical illness as a result of local invasion, widely disseminated disease, or both. (hospitalpharmacyeurope.com)
Immune checkpoint4
- Thus, the KIR3DL3-HHLA2 axis represents a novel immune checkpoint pathway and blockade of KIR3DL3 signaling may be a promising strategy to promote antitumor immunity. (bmj.com)
- Conclusions Collectively, these data demonstrate that the KIR3DL3-HHLA2 pathway is a novel immune checkpoint axis that facilitates tumor escape by attenuating both innate and adaptive antitumor immune responses. (bmj.com)
- Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumor therapy. (bmj.com)
- Immune checkpoint blockers (ICBs) limit the tumor's immune escape yet only for approximately a third of all tumors and, in most cases, for a limited amount of time. (biomedcentral.com)
Promote tumor1
- In this study, we first found that high concentrations of C. tropicalis promote tumor growth in cell cultures and xenografts. (jcancer.org)
Tissue2
- Kingwell K. Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue. (jscimedcentral.com)
- By definition, Schwannian stroma should comprise less than 50% of the tumour tissue to be NB. (hospitalpharmacyeurope.com)
Melanoma1
- In recent years, studies have shown that tumor cell-intrinsic PD-1 plays different roles in the development of melanoma, Liver cancer and lung cancer. (jcancer.org)
Mutations1
- 2 , 3 ] This is perhaps not so surprising considering the fact that cancer is often a multifactorial disease, where tumors acquire a series of mutations. (ens-lyon.fr)
Colorectal1
- Genetic reconstruction of individual colorectal tumor histories. (nature.com)
Effector function1
- By blocking the negative immune regulatory signals mediated by PD-1/PD-L1 pathway, these drugs remove the inhibition of T-cell activation and effector function and vigorously restore antitumor immune responses [ 3 ]. (oncotarget.com)
Cancer immunotherapy1
- Cancer immunotherapy approaches designed to surmount tumor suppression take into consideration the pivotal molecular processes involved in the activation of immune system. (thno.org)
Responses3
- However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. (biomedcentral.com)
- Anti-HIV-1 T cell responses are evaded by continuous mutation of the virus. (scielo.br)
- Vaccine strategies that concentrate on stimulating T cell immunity will at best generate reactive and persisting T cell responses that can suppress virus without preventing infection, limiting or preventing the damage the virus cause. (scielo.br)
Chemotherapy1
- Our previous studies have found that Candida tropicalis ( C. tropicalis ) can promote CRC tumor growth and chemotherapy resistance to oxaliplatin by regulating mismatch repair system. (jcancer.org)
Biology2
- Tumor Biology (2016) 37 (12): 15687. (aacrjournals.org)
- Studying these groups on regular cancer surveillance provides insight into the tumor biology, potential avenues for prevention, and their effectiveness. (aacrjournals.org)
Suppression1
- Enhanced understanding of mechanisms underlying T-cell anergy such as arginine deprivation, immunosuppressive cytokines, defective innate and interferon response pathways, and NKG2D downregulation have all provided new insight into suppression of anti-tumors. (nshealth.ca)
Behavior1
- The IL-33-enhanced-CXCR4 regulatory circuit involves SDF1/CXCR4 signaling activation and modulates tumor behavior. (bvsalud.org)
Prognosis3
- Brain metastases (BM) are the most common tumor within the brain and carry a poor prognosis due to limitations in current treatment options. (abta.org)
- In this study, we systematically assessed DOK5 expression in a variety of tumor forms involving GC, as well as its association with prognosis. (hindawi.com)
- PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. (jscimedcentral.com)
Blockade2
Resistance1
- Resistance to ICBs can be primary for tumors that are intrinsically "invisible" by the immune system, adaptive for tumors that are recognized by the immune system but adapt to it, and truly acquired for tumors that initially respond to the treatment but then progress [ 5 ] reminiscent of cancer immune-editing theory [ 6 ]. (biomedcentral.com)
Cell4
- Qu J, Chen Q, Bing Z, Shen S, Hou Y, Lv M, Wang T. C. tropicalis promotes CRC by down-regulating tumor cell-intrinsic PD-1 receptor via autophagy. (jcancer.org)
- In contrast to species evolution, cancer is a particular case owing to the vast size of tumour cell populations, chromosomal instability and its potential for phenotypic plasticity. (nature.com)
- Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. (jscimedcentral.com)
- Defects in cell-mediated immunity (CMI) and level of immunocompetence are major determinants for development of disease. (medscape.com)
Patients2
- Our proposal is an unprecedented opportunity specifically tailored to patients with BM in which we will obtain detailed tumor blood vessel changes and the genomic basis for such changes during treatment. (abta.org)
- TIME influences the immune escape of cancer, the response to immunotherapy, and the survival rate of patients. (biomedcentral.com)